Video, Portable and Carrier-Grade IP Phones from Grandstream Now Available for ISTRA by Enreach UCaaS Platform
23.2.2021 11:30:00 EET | Business Wire | Press release
Enreach, the fast-growing European unified communications group, has announced that multiple IP phones from Grandstream have been certified for use on its Unified Communications as a Service (UCaaS) platform, ISTRA by Enreach. Through Enreach for Service Providers, partners and their customers have immediate access to portable and video phones from Grandstream, plus carrier-grade devices designed for mass-deployment.
Bertrand Pourcelot, Managing Director at Enreach for Service Providers, said: “Grandstream’s name has become synonymous with IP phones that combine superior quality and ease-of-use, with options to suit a wide variety of budgets and requirements. Grandstream is a good fit for our portfolio of supporting products for the ISTRA by Enreach UCaaS platform, which is already used by approximately one million users via over 100 service providers in 20-plus countries.”
Grandstream IP phones certified for ISTRA by Enreach
Highlights of the ISTRA-certified range include Grandstream’s GXV3300 series of advanced IP video phones for Android, bringing multimedia AV communications to the desktop, with tablet-style functionality and web access.
For greater mobility in the workplace, the cordless WP810 and WP820 are portable WiFi IP phones, providing robust design and comprehensive features. As well as office or home-working environments, these phones are ideal for retail, logistics, medical, security and other vertical markets where portability is a benefit.
When large volumes of handsets are needed, the GRP2600 series of Carrier-Grade IP phones deliver powerful performance, simplicity of use and easy deployment. As well as supporting basic communications, these devices include next generation features for high-end users.
About ISTRA by Enreach
The ISTRA cloud based UCaaS platform is already deployed by over 100 service providers in more than 20 countries with approximately one million users. It is also the foundation for Enreach’s future-facing platform strategy across the entire group, as part of its ambition to be Europe’s UCaaS leader.
Enreach for Service Providers
Based in Sophia-Antipolis, France, Enreach for Service Providers (previously known as Centile Telecom Applications) is a European leader in the development of Cloud PBX and unified communications platforms for operators and integrators. As well as supporting Enreach for Service Providers own service provider customers, ISTRA by Enreach UCaaS platform is the foundation for Enreach’s future-facing strategy across the entire group, as part of its ambition to be Europe’s UCaaS leader. https://enreach.com/en/for-service-providers
About Enreach
Enreach is the parent company of various labels such as Voiceworks, Swyx, Eazit, i4IP, ipnordic, M Mobility, HeroBase, Network Telecom, Botsquad and masvoz. Enreach provides collaboration technology and telecoms services via their reselling and service providing partners or direct brands that are transformative for SMEs and the people that work with them. All brands contribute to intelligent, integrated IT and communication solutions that ensure optimal communication and workflow between organisations. Enreach’s mission is to give businesses access to the best communication and collaboration tools with an easy, user-centric interface built around their specific needs and systems. The group’s products put powerful features in reach of every business, no matter the industry or size, so their employees can focus on getting amazing things done. Enreach is active in the core markets Germany, the Netherlands, Denmark, UK, Spain and France with activities in 25 countries and 950 employees. https://enreach.com/
About Grandstream
Grandstream Networks, Inc. has been connecting the world since 2002 with SIP Unified Communications products and solutions that allow businesses to be more productive than ever before. Our award-winning solutions serve the small and medium business and enterprises markets and have been recognized throughout the world for their quality, reliability and innovation. Grandstream solutions lower communication costs increase security protection and enhance productivity. Their open standard SIP-based products offer broad interoperability throughout the industry, along with unrivaled features and flexibility. Visit www.grandstream.com for more information or connect with us on Facebook, LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005422/en/
Contact information
Media Contacts
Ambrose Communications
Maxine Ambrose
E mail: maxineambrose@ambrosecomms.com
Tel : + 44 7785 280930
Karine Merouze
International Marcoms Manager
Enreach for Service Providers
E-Mail: karine.merouze@enreach.com
Tel: +33 49 723 1265
For Grandstream
Phil Bowers
marketing@grandstream.com
Tel: 1-617-566-9300
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
